China's investigation into alleged corruption at pharmaceutical multi-nationals has widened in recent days. GlaxoSmithKline (GSK), accused last week of paying over $400m in bribes to doctors and lawyers to boost sales, admitted this week that senior executives "appear to have acted outside our processes and controls, which breaches Chinese law". Meanwhile, three AstraZeneca sales executives have been arrested, although the group was claiming early this week that they had no reason to believe the swoop was related to the bribery allegations.
What the commentators said
This affair is certainly starting to look like "a crusade against Western pharmaceutical giants", said Ben Griffiths in the Daily Mail. Could bribery allegations actually be designed to pressurise Western firms into cutting their prices and thus help China cope with a soaring healthcare bill? Note that GSK has now hinted at price cuts in the Chinese market.
What's more, added The Wall Street Journal, the Chinese government's investigation didn't start as a criminal matter, but as a probe into the costs of drugs made by both domestic and foreign pharma groups. A foreign firm was targeted first because "that helps distract attention from a health system that relies on corruption to stay afloat".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Hospitals are forced to keep prices for most services below cost, so drug sales is one of the few areas in which they can make money. They encourage poorly paid doctors to prescribe more drugs by linking bonuses to revenue, while doctors also get kickbacks from drug firms. But instead of changing this "dysfunctional" cause of high drug prices, concluded The Wall Street Journal, China is "taking aim" at the likes of GSK.
-
Christmas at Chatsworth: review of The Cavendish Hotel at BaslowMoneyWeek Travel Matthew Partridge gets into the festive spirit at The Cavendish Hotel at Baslow and the Christmas market at Chatsworth
-
Tycoon Truong My Lan on death row over world’s biggest bank fraudProperty tycoon Truong My Lan has been found guilty of a corruption scandal that dwarfs Malaysia’s 1MDB fraud and Sam Bankman-Fried’s crypto scam
-
Are GSK’s legal troubles a threat to the firm’s survival?Analysis Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
-
GlaxoSmithKline’s first-quarter figures show the company is on track for the yearAnalysis Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
-
Why GSK should turn down Unilever’s billionsNews Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or of anyone else, says Matthew Lynn.
-
Unilever slides and GSK bounces after GSK knocks back £50bn bidNews Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
-
Shake-up at GSK won’t placate investorsNews GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance.
-
A show of support for GlaxoSmithKline's hedge fund fightNews Several large shareholders have said that they will support GlaxoSmithKline in its battle with hedge fund Elliott Management.
-
Activist investor Elliott takes takes a stake in GlaxoNews Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
-
If you'd invested in: Renishaw and GlaxoSmithKlineFeatures Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
